Tu Youyou: from traditional knowledge to the therapeutic standard against malaria

Chinese researcher Tu Youyou demonstrated that tradition can coexist with the scientific method. She started from ancient medical references and subjected them to modern experiments until isolating artemisinin from Artemisia annua. This breakthrough, later optimized through derivatives and combined regimens, became a cornerstone of antimalarial treatment and has helped significantly reduce malaria mortality, earning her the 2015 Nobel Prize in Physiology or Medicine.

Scientific contribution

Tu approached historical sources with a critical eye and translated them into verifiable hypotheses. She adjusted extraction techniques—at low temperature and using appropriate solvents—to preserve the active principle, and linked in vitro and in vivo assays to obtain reproducible results. It was not a “lucky find”: it was method, control, and repetition.

The next step was bringing chemistry to the patient. From the original molecule, derivatives with improved pharmacological properties were developed (such as artesunate, artemether or dihydroartemisinin), and artemisinin-based combination therapies (ACT) were established. The goal: greater efficacy and less resistance, by combining drugs with complementary mechanisms and half-lives.

With accumulated clinical evidence, international guidelines adopted these regimens and national programs integrated them as a public health standard. Where drug quality, access, and adherence are ensured, the impact is sustained and measurable.

Impact and perspectives

The Tu Youyou case also left a way of working: natural products can give rise to modern medicines when investigated with quality, reproducibility, and safety criteria. From phytochemical screening to analytical characterization, from stability to impurities, the process is as important as the result.

The challenge is not over. The emergence of resistance requires continuous surveillance, optimization of combinations, and protection of supply chains (API quality, fight against counterfeits, availability). In parallel, research explores new derivatives and therapeutic partners to maintain the advantage over the parasite.

From Cymit Química, for your research

We support research in infectious diseases with molecular and cellular biology reagents, analytical and phytochemical standards, and antibiotics for development and therapy. We are at your disposal to assist you at any stage of your project.